Coding

Part:BBa_K4117022:Design

Designed by: Bojun Xiong,Yueyao Qi   Group: iGEM22_BNU-China   (2022-09-30)
Revision as of 08:10, 12 October 2022 by Yl (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


CYP2C19


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal PstI site found at 127
    Illegal PstI site found at 1357
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal PstI site found at 127
    Illegal PstI site found at 1357
    Illegal NotI site found at 284
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 1395
    Illegal BamHI site found at 3
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal PstI site found at 127
    Illegal PstI site found at 1357
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal PstI site found at 127
    Illegal PstI site found at 1357
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

Since this subunit has been proved to be expressed successfully, we did not re-engineer this protein gene.

Source

We design the DNA sequence based on the amino acid sequence according to E.coli codon preference.The amino acid sequence is from UniProt:P11712

References

[1]Patilea-Vrana GI, Anoshchenko O, Unadkat JD. Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. Drug Metab Dispos. 2019 Mar;47(3):249-256. doi: 10.1124/dmd.118.085548. Epub 2018 Dec 19. PMID: 30567877; PMCID: PMC6374540.

[2]Gasse A, Vennemann M, Köhler H, Schürenkamp J. Toxicogenetic analysis of Δ9-THC-metabolizing enzymes. Int J Legal Med. 2020 Nov;134(6):2095-2103. doi: 10.1007/s00414-020-02380-3. Epub 2020 Jul 25. PMID: 32712703; PMCID: PMC7578149.

[3]Doohan PT, Oldfield LD, Arnold JC, Anderson LL. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. AAPS J. 2021 Jun 28;23(4):91. doi: 10.1208/s12248-021-00616-7. PMID: 34181150.